University of California

Susan E Bennett

Bruce D Hammock

Christophe H Morisseau

In-Hae Kim

Takaho Watanabe

Seung-Jin Ma

Judith S Stern

The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase ('sEH'). Optionally, a cis-epoxyeicosantrienoic acid ('EET') can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.

Growing community of inventors

Davis, CA, United States of America

Susan E Bennett